Long-term bioavailability after a single oral or intramuscular administration of 600,000 IU of ergocalciferol or cholecalciferol: Implications for treatment and prophylaxis

78Citations
Citations of this article
71Readers
Mendeley users who have this article in their library.

Abstract

Context: We previously showed that a single high dose of oral (po) cholecalciferol (D3) sharply increases serum 25-hydroxyvitamin D [25(OH)D]. Objective: We evaluated the long-term bioavailability and metabolism of a single po or intramuscular (im) high dose of ergocalciferol (D2) or D3. Design: This was a prospective intervention study. Setting: The study was conducted in an ambulatory care setting. Patients: Participants were 24 subjects with hypovitaminosis D. Interventions: A single dose of 600,000 IU of po or im D2 or D3 was administered. Main Outcome Measures: Serum 25(OH)D and 1,25-dihydroxyvitamin D [1,25(OH)2D] were measured at baseline and at days 30, 60, 90, and 120 by RIA. Serum 1,25(OH)2D2, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], 24,25-hydroxyvitamin D2 [24,25(OH)D2], and 24,25-hydroxyvitamin D3 [24,25(OH)D3] were measured by liquid chromatography-tandem mass spectrometry in a subgroup of patients receiving the po formulations. Results: The areas under the curve of 25(OH)D after D3 were significantly higher than those after D2 (P < .0001). Serum 25(OH)D basal difference significantly increased at day 30 with po D2 and D 3 (P < .01 and P < .0001) and up to day 90 with po D 3 (P < .01). The im formulations produced a slow increased, and values peaked at day 120 relative to the other time points (P < .0001). We found a decrease in 1,25(OH)2D at day 30 (P < .05) and up to day 120 (P < .001) and an increase in 1,25(OH)2D2 at day 30 (P < .01) and up to day 120 (P < .01) after po D2. Oral D 2 and D3 produced increases in 24,25(OH)D2 and 24,25(OH)D3, respectively, at day 30 (P < .001). Conclusions: A po dose of 600,000 IU of D2 or D3 is initially more effective in increasing serum 25(OH)D than the equivalent im dose and is rapidly metabolized. Our RIA assay for 1,25(OH)2D may not recognize 1,25(OH)2D2. Copyright © 2013 by The Endocrine Society.

References Powered by Scopus

Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline

8377Citations
N/AReaders
Get full text

Hypovitaminosis D in medical inpatients

1318Citations
N/AReaders
Get full text

Prevalence of vitamin D insufficiency in an adult normal population

1295Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Global consensus recommendations on prevention and management of nutritional rickets

878Citations
N/AReaders
Get full text

Global consensus recommendations on prevention and management of nutritional rickets

187Citations
N/AReaders
Get full text

Vitamin d sources, metabolism, and deficiency: Available compounds and guidelines for its treatment

149Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Cipriani, C., Romagnoli, E., Pepe, J., Russo, S., Carlucci, L., Piemonte, S., … Minisola, S. (2013). Long-term bioavailability after a single oral or intramuscular administration of 600,000 IU of ergocalciferol or cholecalciferol: Implications for treatment and prophylaxis. Journal of Clinical Endocrinology and Metabolism, 98(7), 2709–2715. https://doi.org/10.1210/jc.2013-1586

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 24

65%

Researcher 7

19%

Professor / Associate Prof. 6

16%

Readers' Discipline

Tooltip

Medicine and Dentistry 19

45%

Agricultural and Biological Sciences 11

26%

Pharmacology, Toxicology and Pharmaceut... 7

17%

Biochemistry, Genetics and Molecular Bi... 5

12%

Save time finding and organizing research with Mendeley

Sign up for free